Antileishmanial Effects of Synthetic EhPIb Analogs Derived from the Entamoeba histolytica Lipopeptidephosphoglycan

With an estimated number of new cases annually of approximately 1.4 million, leishmaniasis belongs to the most important parasitic diseases in the world. Nevertheless, existing drugs against leishmaniasis in general have several drawbacks that urgently necessitate new drug development. A glycolipid...

Descripción completa

Detalles Bibliográficos
Autores principales: Fehling, Helena, Choy, Siew Ling, Ting, Frederic, Landschulze, Dirk, Bernin, Hannah, Lender, Sarah Corinna, Mühlenpfordt, Melina, Bifeld, Eugenia, Eick, Julia, Marggraff, Claudia, Kottmayr, Nadine, Groneberg, Marie, Hoenow, Stefan, Sellau, Julie, Clos, Joachim, Meier, Chris, Lotter, Hannelore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318009/
https://www.ncbi.nlm.nih.gov/pubmed/32393489
http://dx.doi.org/10.1128/AAC.00161-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318009/
https://www.ncbi.nlm.nih.gov/pubmed/32393489
http://dx.doi.org/10.1128/AAC.00161-20

Ejemplares similares